Andrew A. Nierenberg Joins the 4M Therapeutics Scientific Advisory Board

[Skillman, NJ & Boston, MA]: 4M Therapeutics Inc. (4MTx) today announced that Andrew A. Nierenberg has joined its Scientific Advisory Board

Dr. Nierenberg holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Massachusetts General Hospital, is Director of the Dauten Family Center for Bipolar Treatment Innovation, and is a Professor at Harvard Medical School. Dr. Nierenberg’s primary interests are treatment-resistant depression, bipolar depression, and innovative treatments for mood disorders.

"I am excited to join the team at 4M Therapeutics", says Dr. Nierenberg. "Together we have world-class scientists, strong executive leadership, and a wonderful opportunity to develop new therapies for patients."

"It is a pleasure to have Dr. Nierenberg join us”, says Pablo Lapuerta, Founder & CEO at 4MTx. "This year 4MTx made a lot of progress in advancing towards clinical development, and Dr. Nierenberg’s contribution as a world expert in bipolar disorder prepares us well for the future."

About 4MTx: 4M Therapeutics Inc. is a startup biotech company based on the principle that the study of human brain cells represents an important advance in neuroscience discovery. 4MTx has developed a pipeline of small molecules by studying their effects on brain cells derived from human induced pluripotent stem cells. The initial focus is bipolar disorder and Alzheimer's disease, conditions where targeted drug discovery can support and improve neuroplasticity and neurogenesis. The scientific founders are world-leaders in neurobiology, chemistry, and the pharmacology of neuroplasticity. For more information, please visit www.4mtx.net and engage with us on LinkedIn.